Ben Miller's questions to Illumina Inc (ILMN) leadership • Q3 2024
Question
Ben Miller, on behalf of Mason Carrico, asked about the opportunity in single-cell sequencing and how the acquisition of Fluent Biosciences is expected to either grow the market or take share from competitors.
Answer
CEO Jacob Thaysen stated that Fluent's instrument-free, high-volume workflow should help expand the overall single-cell market. He affirmed Illumina's commitment to supporting its existing single-cell partners, emphasizing the primary goal is to ensure customer success on Illumina platforms, which will drive the entire market forward. He expressed a bullish outlook on the single-cell opportunity.